A vaccine to protect against pneumonia and meningitis in adults is expected to be launched this year.
Pfizer is preparing to market Prevnar 13 – a vaccine widely used to protect infants and young children against pneumococcal bacteria – for adults in 2011.
The vaccine is set to dominate the pneumococcal market within the next decade, it is reported.
Pneumovax 23 could quickly be replaced as the gold standard for the primary immunisation of elderly and high-risk adults.
The anticipated market shake-up will leave only marginal roles for Prevnar 13’s competitors, it is reported.
Use of the quadrivalent meningococcal conjugate vaccine (MenACWY) is expected to be limited in the seven major markets.
The US are unlikely to recommend routine MenACWY vaccination of infants, and the vaccine will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs.